Breast Cancer Treatments

Find Breast Cancer Treatments

Brand Name

Doxil

Generic Name

DOXOrubicin

View Brand Information

FDA approval date: December 23, 1987

Classification: Anthracycline Topoisomerase Inhibitor

Form: Injection, Injectable

What is Doxil (DOXOrubicin)?

Doxorubicin is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug, Biological

Study Phase: Phase 3

Summary: Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) mean...

Phase II Study of Dose-Adjusted EPOCH ± Rituximab + Ponatinib for Adults With Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Biological, Procedure, Drug

Study Phase: Phase 2

Summary: This phase II trial tests the effect of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) with or without rituximab plus ponatinib in treating patients newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia or lymphoma (ALL). Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certai...

Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Who is this study for: Adult patients with Hodgkin's Lymphoma

Enrollment Status: Recruiting

Publish Date: April 16, 2026

Intervention Type: Drug, Procedure

Study Drugs: Pembrolizumab, Gemcitabine, Vinorelbine, Doxorubicin

Study Phase: Phase 2

Summary: The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

View All Clinical Trials

Related Latest Advances

Phototherapeutic β-Cyclodextrin-Branched Polymer Releasing Nitric Oxide with Fluorescent Self-Reporting and Its Combination with Doxorubicin.

Journal: Biomacromolecules

Published: April 15, 2026

Correction to: Albumin nanoparticles-mediated doxorubicin delivery enhances the anti-tumor efficiency in ovarian cancer cells through controlled release.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: April 14, 2026

Multiomics Analysis Reveals the Protective Effect of a Novel Bioactive Peptide (BP1) in Cardiomyopathy Using a Zebrafish Model.

Journal: Journal of proteome research

Published: April 14, 2026

View All Latest Advances